Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated cation channels — distinct from muscarinic ACh (Gq/Gi GPCRs, muscarinic receptor subtypes). Three major locations: (1) Neuromuscular junction (NMJ) — exclusively α1β1δε (adult) or α1β1δγ (fetal/denervated) muscle-type pentamers; succinylcholine, rocuronium, vecuronium, pancuronium, atracurium = NMJ-targeted neuromuscular blockers. (2) Autonomic ganglia — α3β4 (with α5 modulatory subunit); ganglionic blockers (historical: hexamethonium, trimethaphan) lost favor due to side-effect breadth. (3) CNS — α4β2 (dominant high-affinity nicotine binding; addiction + cognition target — varenicline partial agonist for smoking cessation) and α7 homopentamer (rapidly desensitizing; cognitive + cholinergic anti-inflammatory pathway via spleen vagal-nicotinic axis). Receptor states: closed → open (ms) → desensitized (s–min) → closed; chronic nicotine + α4β2-selective partial agonists drive desensitization → paradoxical functional block of fast-onset activation. Biased modulators: PAMs (galantamine on α7 and some α4β2) enhance ACh response without direct agonism. Neuromuscular blockade reversal: AChEi (neostigmine, edrophonium, pyridostigmine) restore ACh competition; sugammadex sequesters rocuronium/vecuronium directly. Smoking cessation: varenicline α4β2 partial agonist (Champix/Chantix); bupropion adjunct (DA/NE reuptake + nAChR antagonist). Cross-links: acetylcholine axis (ACh synthesis + release upstream), neuromuscular junction blockade (clinical use).
Organ Systems
nervous
musculoskeletal
immune-hematologic
Pathway Steps
ACh release at synaptic cleft → nAChR binding (2 ACh per pentamer required) — via two non-equivalent α-subunit binding sites; cooperative activation. Nicotinic receptors are pentameric ligand-gated ion channels — the fast, ionotropic arm of cholinergic signaling. Two ACh molecules must bind at subunit interfaces to open the pore, giving a steep, cooperative response. The varied subunit combinations generate subtypes with distinct pharmacology.
nAChR open state (ms) → Na⁺/Ca²⁺/K⁺ influx → depolarization — via high cation permeability; α7 has highest Ca²⁺ fraction (signaling role). Agonist binding opens the channel for milliseconds, letting Na⁺ and Ca²⁺ in and K⁺ out — a depolarizing cation current. The Ca²⁺ permeability matters: it lets nAChRs trigger downstream signaling (transmitter release, gene expression) beyond simple electrical excitation.
sustained ACh / agonist exposure → desensitized state (slow recovery) — via chronic nicotine drives this — paradoxical functional block. With sustained agonist exposure, nAChRs enter a desensitized, non-conducting state that recovers slowly. This is pharmacologically central: it explains nicotine tolerance, the depolarizing block of succinylcholine, and why a steady agonist (a nicotine patch) behaves very differently from phasic ACh.
NMJ nAChR (α1β1δε) → end-plate depolarization → muscle contraction — via AChE hydrolysis terminates signal; NMB drugs block here. The muscle-type receptor (α1β1δε) at the neuromuscular junction converts motor-nerve ACh into end-plate depolarization and contraction. It is the target of non-depolarizing blockers (rocuronium, vecuronium) used for surgical paralysis, and the autoantigen in myasthenia gravis.
α7 nAChR (CNS / immune) → cognitive + anti-inflammatory cholinergic pathway — via vagal-spleen anti-inflammatory pathway; rapid desensitization characteristic. The homomeric α7 receptor, highly Ca²⁺-permeable, is found in CNS (cognition) and on macrophages, where it mediates the cholinergic anti-inflammatory pathway — vagal ACh suppressing cytokine release. This links nervous and immune systems and makes α7 a target for cognition and inflammatory disease.
α4β2 nAChR (CNS) → nicotine reward circuit → addiction — via mesolimbic DA release via VTA α4β2; varenicline partial agonist target. The α4β2 subtype is the high-affinity nicotine receptor in the brain’s reward circuitry; nicotine acting here drives dopamine release and addiction. It is the target of smoking-cessation drugs — varenicline is a partial agonist that both relieves craving and blunts nicotine’s reward.